• Swallow the tablet whole with a full glass of water.
• Avoid chewing or crushing the tablet.
• Take the medicine either before or after meals.
• Follow your doctor’s instructions on the timing and dosage of the medicine.
Renvilda 50 Tablet is primarily indicated for the management of type 2 diabetes mellitus in adults. This formulation belongs to the pharmacological class of dipeptidyl peptidase-4 (DPP-4) inhibitors.
Renvilda 50 Tablet is prescribed for:
• Controlling blood glucose levels in adults with type 2 diabetes mellitus
• Enhancing the effectiveness of diet and exercise regimens in the management of type 2 diabetes
• Monotherapy when lifestyle modifications alone are insufficient for glycaemic control
• Combination therapy with other antidiabetic agents to optimise glycaemic management
• Swallow the tablet whole with a full glass of water.
• Avoid chewing or crushing the tablet.
• Take the medicine either before or after meals.
• Follow your doctor’s instructions on the timing and dosage of the medicine.
Renvilda 50 Tablet is taken orally.
Renvilda 50 Tablet may result in side effects, including:
• Headache
• Dizziness
• Nasopharyngitis
• Upper respiratory tract infection
• Arthralgia
Renvilda 50 Tablet contains vildagliptin (50 mg), which exhibits its pharmacological effects through several mechanisms:
• DPP-4 Inhibition: Vildagliptin acts by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), preventing the degradation of incretins.
• Increase in Active Incretins: By inhibiting DPP-4, vildagliptin enhances the levels of active incretins, which stimulate pancreatic insulin secretion in response to elevated blood glucose levels.
• Suppression of Glucagon Secretion: Vildagliptin further reduces hepatic glucose production by decreasing glucagon secretion, thereby aiding in maintaining optimal blood glucose levels.
Exercise caution and consult your doctor before taking Renvilda 50 Tablet during pregnancy.
Consult your doctor before use while breastfeeding to assess potential risks and benefits.
Avoid alcohol consumption as it may increase the risk of lactic acidosis and hypoglycaemia.
Vildagliptin is not recommended in patients with liver impairment. Seek medical advice before use.
It should be used with caution in patients with kidney impairment. Consultation with a doctor is recommended.
If dizziness occurs after taking this medicine, avoid operating heavy machinery or driving.
Contraindicated in individuals with hypersensitivity to vildagliptin or any excipients.
Not indicated for use in individuals below 18 years of age.
Older adults should use Renvilda 50 Tablet under medical supervision due to increased susceptibility to adverse effects.
Drug-Drug Interactions
• Sulfonylureas: Co-administration may potentiate the hypoglycaemic effect, leading to hypoglycaemia.
• Beta-Blockers: Combining with vildagliptin may increase the risk of hypoglycaemia.
Drug-Disease Interactions
• Congestive Heart Failure: Careful monitoring is advised.
Daily Dose
• Take Renvilda 50 Tablet as directed by your doctor. The dosage may change based on individual factors such as the severity of the condition and response to treatment. It is important to follow the prescribed dosage and not exceed it without consulting your doctor.
Missed Dose
• If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double the dose to make up for a forgotten dose.
Overdose
• Common overdose effects may include headaches, dizziness, and nausea. Seek medical attention if an overdose is suspected.
• Store at a temperature not exceeding 30°C.
• Keep in a dry place, shielded from moisture and direct light.
• Keep out of reach of children.
• Refer to the expiry date on the packaging and use the product before this date.
• Maintain a diet rich in fibre, including fruits, vegetables, and whole grains, to aid in blood sugar control.
• Engage in regular physical activity, such as a 30-minute brisk walk daily, to support glucose regulation and enhance overall fitness.